The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Mon., Feb. 6, 2:18 AM

Slide #6. Phio Pharmaceuticals Corp. (NASDAQ:PHIO) 1 for 12 Reverse Split

Announced: 1/25/2023
Stock Split: 1 for 12
Record Date: 1/25/2023
Pay Date: 1/26/2023
PHIO Optionable?: Yes

Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
PHIO Detailed Information Page & Split History »

Company Name: 
Phio Pharmaceuticals Corp
Website: 
www.phiopharma.com
Sector: 
Biotechnology
Number of ETFs Holding PHIO: 
1
Total Market Value Held by ETFs: 
$953503
Total Market Capitalization: 
$7.00M
% of Market Cap. Held by ETFs: 
13.62%

Open the PHIO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PHIO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Splits Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2023, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.